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A Dual Pathogenic Mechanism 
Links Tau Acetylation to Sporadic 
Tauopathy
Hanna Trzeciakiewicz1, Jui-Heng Tseng2, Connor M. Wander2, Victoria Madden3, 
Ashutosh Tripathy1, Chao-Xing Yuan4 & Todd J. Cohen5
Tau acetylation has recently emerged as a dominant post-translational modification (PTM) in 
Alzheimer’s disease (AD) and related tauopathies. Mass spectrometry studies indicate that tau 
acetylation sites cluster within the microtubule (MT)-binding region (MTBR), suggesting acetylation 
could regulate both normal and pathological tau functions. Here, we combined biochemical and  
cell-based approaches to uncover a dual pathogenic mechanism mediated by tau acetylation. We 
show that acetylation specifically at residues K280/K281 impairs tau-mediated MT stabilization, and 
enhances the formation of fibrillar tau aggregates, highlighting both loss and gain of tau function. Full-
length acetylation-mimic tau showed increased propensity to undergo seed-dependent aggregation, 
revealing a potential role for tau acetylation in the propagation of tau pathology. We also demonstrate 
that methylene blue, a reported tau aggregation inhibitor, modulates tau acetylation, a novel 
mechanism of action for this class of compounds. Our study identifies a potential “two-hit” mechanism 
in which tau acetylation disengages tau from MTs and also promotes tau aggregation. Thus, therapeutic 
approaches to limit tau K280/K281 acetylation could simultaneously restore MT stability and ameliorate 
tau pathology in AD and related tauopathies.
Tau proteins form hallmark neurofibrillary tangles (NFTs) and other pathological lesions that characterize 
Alzheimer’s disease (AD) and related tauopathies. Six tau isoforms are present in the brain containing either 
three (3R-tau) or four (4R-tau) repeat domains that together with the flanking regions mediate physiological 
tau-microtubule (MT) binding and confer MT stability1,2. Tau phosphorylation in regions mostly flanking the 
MT-binding region (MTBR) is the dominant mechanism thought to control tau function. However, tau is sub-
ject to a myriad of other post-translational modifications (PTMs) (e.g. ubiquitination, acetylation, methylation, 
glycosylation, polyamination)3 that alter tau’s biochemical properties, indicating that a complex tau PTM profile 
coordinately regulates tau function, which could ultimately determine aberrant tau pathology in diseased brains.
We and others demonstrated that tau is subject to acetylation within the lysine-rich MTBR4–9. While the full 
complement of enzymes controlling tau acetylation is not well-characterized, in vitro and cell-based experiments 
showed that CREB-binding protein (CBP) or the highly homologous p300 acetylates tau with high affinity in 
the MTBR4,8,10. In the complete absence of CBP or p300, tau also possesses an intrinsic ability to self-acetylate 
similar to that observed with auto-regulated acetyltransferases (e.g. MYST-family), implying that the energet-
ically favorable acetyl group transfer may occur if acetyl-CoA levels are present at sufficient concentrations in 
the cytoplasm where tau is enriched10. Counter-acting tau acetylation, the deacetylases HDAC6 and SIRT1 have 
been shown to deacetylate tau in vitro and in cultured cells, highlighting a potential neuroprotective role for tau 
deacetylation by HDACs/Sirtuins4,8.
Several studies have implicated tau acetylation in the formation and maturation of NFTs4,6,8,11,12. Using an 
acetylation-specific tau antibody recognizing residue K280, tau lesions were readily detected in all 4R-tauopathies 
analyzed including AD, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and a panel of 
familial AD cases, but not 3R-tau predominant Pick’s disease (PD) lacking exon 10 that harbors the K280 residue4. 
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Supporting a pathological role for tau acetylation, CBP-acetylated tau proteins composed solely of the MTBR 
(tau-K18) showed increased tau filament formation as assessed by sedimentation assays, elevated Thioflavin T 
(ThT) reactivity, and the formation of tau fibrils by electron microscopy (EM).
The affinity for particular acetylated lysine residues or the exact stoichiometry of tau acetylation may be crit-
ical determinants of tau aggregation5. However, the consistent detection of K280-acetylated insoluble tau in sev-
eral tau transgenic mouse models4,13,14 and human tauopathy brain samples4,6,11,12 supports the notion that tau 
K280 acetylation increasingly correlates with tau pathogenesis. More recently, tau acetylation-mimicking muta-
tions at other prominent sites including K174, K274, K281 induced a series of AD-like deficits including synaptic 
dysfunction, neuronal loss, and cognitive impairments in viral-transduced and transgenic mouse models, sup-
porting an acetylation-mediated pathological cascade15,16. A detailed understanding of how acetylation regulates 
tau function could foster new avenues to limit acetylated tau as plausible therapeutic strategies.
Early biochemical studies showed that the positively charged tau residues K280 and K281 physically engage 
MTs, highlighting the double lysine containing PHF6* motif (275VQIINK/K281) in exon 10 as a hotspot for tau-MT 
binding in addition to promoting tau aggregation17. The importance of residue K280 is reflected by the genetic 
deletion of this residue in FTDP-17 class dementia (Δ K280)18 or by the acetylation of residues K280 or K281, 
as we observed in AD and other tauopathies4. Either lysine deletion or acetylation is predicted to neutralize the 
overall positive lysine charge within this region, potentially abrogating tau-MT binding. However, in contrast 
to the relatively rare genetic Δ K280 mutation, positive K280-acetylated lesions are observed in most sporadic 
4R-tauopathies analyzed to date11,12 and may represent a common feature of AD and other tauopathies.
Here, we provide evidence that tau K280/K281 acetylation induces pathogenic hallmarks consistent with both 
loss and gain of tau-mediated toxicity. Surprisingly, we show that tau acetylation alters phosphorylation at res-
idues S202/T205 (comprising the AT8 epitope), indicating acetylation-dephosphorylation cross-talk. Using a 
series of biochemical approaches, we found that K280/K281 acetylation impaired tau-mediated MT assembly 
function and also significantly enhanced tau aggregation. Our results highlight the PHF6* double lysine motif as 
a critical hotspot playing a dual role in normal and pathological tau function. Therefore, modulating the acetyla-
tion machinery to limit K280/K281 acetylation could provide therapeutic benefits in AD and other tauopathies.
Results
Tau acetylation modulates tau phosphorylation status. Full-length 2N4R-tau (also referred to as 
tau-T40) was co-expressed in cultured QBI-293 cells in the presence of wild-type CBP or a catalytically inac-
tive CBP mutant (harboring L1435A/D1436A mutations, referred to as CBP-LD). Surprisingly, we observed that 
CBP-acetylated tau led to specific loss of the slower migrating ~75 kD tau species, initially detected using total tau 
antibodies, which potentially reflected reduced phosphorylation mediated by tau acetylation, an effect that was 
not observed with CBP-LD that is unable to facilitate tau acetylation (Fig. 1a, Supplementary Fig. S1). Subsequent 
immunoblotting showed near complete loss of AT8 immunoreactivity as well as loss of higher mobility ~75 kDa 
tau bands using a series of other phospho-tau antibodies.
Tau contains four prominent acetylation sites (K163, K280, K281, and K369) that were previously identified by 
mass spectrometry of immunopurified tau from cultured cells4. Thus, we introduced acetylation-mimics (4KQ), 
non-mimics (4KR), or a double lysine deletion (Δ K280/K281), which either maintain (e.g. K → R) or reduce 
(e.g. K → Q or Δ KK) the positive charge within this region. The tau proteins were expressed alone or in combi-
nation with a panel of enzymes that modify tau including acetyltransferases/deacetylases (CBP and HDAC6) and 
kinases/phosphatases (GSK3 and PP2A), and analyzed by immunoblotting (Fig. 1b and c, Supplementary Fig. S1). 
Similar to CBP-acetylated tau, acetylationmimic tau at either K280/K281 (2KQ) or all four lysines (4KQ), or 
surprisingly deletion of K280/K281 altogether (Δ KK), caused similar loss of S202/T205 phosphorylation 
(Fig. 1b and c). Supporting the involvement of PP2A phosphatases in acetylation-induced dephosphorylation, 
over-expression of a PP2A targeting subunit (PP2A-B56α) led to S202/T205 dephosphorylation (Fig. 1b), while 
the PP2A inhibitor okadaic acid (OA) restored S202/T205 immunoreactivity in cells expressing either Δ KK, 
2KQ, or 4KQ mutants (Fig. 1c). Thus, either loss of the K280/K281 positive charge or their neutralization via 
acetylation is sufficient to promote dephosphorylation at the AT8 epitope.
To evaluate whether tau acetylation reduced AT8 immunoreactivity in neurons, we generated GFP-tagged 
versions of WT tau-T40 (WT-tau-GFP) or the 4KQ acetylation-mimic (4KQ-tau-GFP). As shown in Fig. 1d, 
WT tau expression in primary cortical neurons is pan-neuronal while AT8 immunoreactivity is predomi-
nantly restricted to the proximal axonal and somato-dendritic compartments, as previously noted19, likely 
reflecting enhanced PP2A activity in more distal regions of the axonal compartment. In contrast, expres-
sion of the acetylation-mimic 4KQ-tau showed reduced AT8-positive immunoreactivity, including within 
the somato-dendritic compartment of 4KQ-tau-GFP transfected neurons (Fig. 1d, see arrows). Thus, tau 
acetylation within the MTBR modulates distant tau phosphorylation status, potentially by generating a 
MT-dissociated cytosolic tau pool that is more susceptible to PP2A-mediated dephosphorylation. To evaluate 
whether tau acetylation leads to MT dissociation, we sought to examine downstream functional consequences 
on MT-assembly and pathological tau aggregation.
Tau acetylation-mimics impair physiological MT assembly activity. Tau residues K280 and K281 
within the PHF6* double lysine motif were shown to directly contact and stabilize charge interactions between 
tau and MTs17. Therefore, we hypothesized that K280/K281 acetylation, and hence neutralization of this positive 
charge, would impair MT stabilizing activity, leading to cytosolic accumulation and loss of normal tau func-
tion. First, we assessed whether both lysines K280 and K281 could be subject to acetylation by mass spectrom-
etry analysis of CBP-acetylated full-length tau-T40 from cultured cells4. Indeed, in addition to singly acetylated 
peptides, we identified a prominent tryptic tau peptide in which K280/K281 were doubly acetylated, suggesting 
that K280/K281 are subject to either individual or tandem acetylation (Fig. 2a and Supplementary Fig. S2). In 
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vitro acetylation reactions using radiolabeled [14C]-acetyl-CoA showed that the 3R-tau repeat domain (tau-K19), 
which lacks the 2nd MTBR repeat containing residues K280/K281, or the 4R-tau repeat domain (tau-K18) con-
taining a deletion of K280/K281 (referred to as Δ KK) led to slightly reduced overall tau acetylation levels (Fig. 2b 
and c, Supplementary Fig. S3), highlighting the K280/K281 residues as two of the more prominent acceptor sites 
among the > 20 tau lysines that are subject to acetylation in vitro.
Figure 1. Tau acetylation modulates tau phosphorylation at specific epitopes. (a–c) Immunoblot analysis 
and quantification using the indicated tau antibodies for (a) cells expressing WT tau-T40 and either an active 
form of CBP or a catalytically inactive form of CBP (CBP-LD), (b) cells co- expressing tau-T40 (WT, Δ KK, 
4KQ, or 4KR) and tau modifying enzymes, and (c) cells expressing tau-T40 (WT, Δ KK, 2KQ, 4KQ, or 4KR) and 
treated with control (DMSO) or okadaic acid (OA), where indicated. Solid black arrows highlight the ~75 kDa 
phospho-tau species that is reduced upon acetylation. Statistical significance was assessed using a student 
t-test (****p < 0.0001). Cropped images from full size immunoblots are provided in panels a–c. Full-length 
immunoblots are presented in Supplementary Fig. S1. (d) Immunofluorescence microscopy of primary cortical 
neurons expressing WT-tau-GFP (left) or 4KQ-tau-GFP (right) detecting phosphorylated tau (AT8). White 
arrows identify transfected neurons. Scale bar, 50 µm.
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To further assess tau-MT regulation, we examined whether acetylation-mimic or non-mimic mutations at 
K280/K281, either singly or in combination, could alter MT assembly function. Tubulin polymerization reactions 
were performed using recombinant WT tau-K18 or K280/K281 mutants containing acetylation-mimic (K → Q) 
or non-mimic (K → R) mutations and MT assembly was assessed by optical density (O.D) readings (Fig. 2d)20. 
As expected, WT tau promoted tubulin assembly into polymerized MTs. In contrast, the single K280Q mutation 
impaired tau-mediated MT assembly by ~50%, while the double K280/281Q mutant showed near complete abro-
gation of MT assembly activity to baseline levels, similar to assembly reactions lacking tau altogether (Fig. 2d). 
Notably, the non-mimics containing single K280R or double 2KR mutations, which maintain the positive charge 
at residues K280/K281, showed either no effect or a mild enhancement of MT assembly kinetics (Fig. 2e). These 
results indicate that acetylation-mimics induce charge neutralization at K280/K281 and impair tau-mediated 
stabilization of MTs.
Tau acetylation-mimics promote tau aggregation. Given that acetylated tau is detected within 
NFTs in AD brain4,11,12, we next investigated whether acetylation might promote tau aggregation, as our 
Figure 2. Tau acetylation-mimics impair tau-mediated MT assembly. (a) Peptide spectra depicting 
doubly acetylated K280 and K281 (275VQIINKKLDLSNVQSK290) from CBP-acetylated tau proteins4. Ion 
scores are provided in Supplementary Fig. S2. (b,c) Autoradiography and Coomassie blue staining of (b) WT 
4R-tau-K18 and 3 R-tau-K19 or (c) WT tau-K18 and tau-K18 Δ KK (containing deletion of residues K280 
and K281). Cropped images from full size gels are provided in panels (b,c). Full-length gels are presented 
in Supplementary Fig. S3. (d,e) Light scattering assay in the presence of tau-K18 proteins detecting tubulin 
polymerization, as determined by absorbance readings at 350 nm (No Tau, X (N = 7); WT, ♦ (N = 9); K280Q, 
●  (N = 8); 2KQ, ▲ (N = 4); K280R, ◯ (N = 7); 2KR, Δ (N = 6)). Error bars indicate s.d. of the mean. Statistical 
significance was assessed using a student t-test as follows: WT vs. K280Q (***p < 0.0001); WT vs. K280R (ns, 
p = 0.36); K280Q vs. K280R (***p < 0.0001); WT vs. 2KR (**p < 0.0072); WT vs. 2KQ (***p < 0.0001); 2KQ vs. 
2KR (***p < 0.0001).
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previous study using CBP-acetylated tau suggested that fully acetylated tau induced tau aggregation in vitro4, 
however, the critical residues mediating this effect remained unclear. In vitro heparin-induced sedimentation 
assays were performed using acetylation-mimic and non-mimic tau proteins as well as the aggregate-prone 
familial P301L mutant. WT and K280R non-mimic tau-K18 proteins transitioned to the pellet fraction 
by 8 h. Strikingly, the K280Q mutant showed remarkably accelerated sedimentation kinetics and was near 
~100% pelleted by 1 hr, an effect that was similarly observed with the positive control P301L mutant (Fig. 3a, 
Supplementary Fig. S4). Consistent with the sedimentation results, ThT fluorescence measurements detected 
robust tau aggregation that was ~5–6 fold higher for K280Q and P301L proteins at 1 h and remained ele-
vated for the duration of the 8 h incubation period (Fig. 3b). The single K280Q and double K280/K281Q 
mutants showed comparable in vitro aggregation kinetics within this accelerated 0–1 h time-frame (data not 
shown). These results were further evaluated using full-length tau-T40 proteins containing single K280Q 
acetylation-mimic or P301L mutations. We observed enhanced transition to the pellet fraction for T40-K280Q 
and T40-P301L by 1 d (Fig. 3c, Supplementary Fig. S4), which was further corroborated by ThT fluorescence 
(Fig. 3d). Thus, K → Q substitutions within the critical PHF6* motif, in the apparent absence of other tau 
PTMs, appears sufficient to accelerate tau aggregation in vitro.
Negative staining electron microscopy (EM) was performed to visualize fibril formation of WT, K280Q, 
and P301L tau-K18 at various time-points (Fig. 4). After 2 h incubation, only sparse WT fibrils were 
detected, in agreement with slower kinetic rates of aggregation. In contrast, numerous dense networks of 
mutant K280Q and P301L fibrils were observed after 2 h incubation, consistent with the accelerated sedi-
mentation and ThT analysis for these two mutants. Furthermore, even after 4 h incubation, WT fibrils were 
not abundant, while the K280Q and P301L mutants continued to accumulate robust negatively stained 
filaments (Fig. 4). We were unable to detect robust K280R fibrils at any early time points, consistent with 
delayed aggregation kinetics.
Since tau K280 acetylation is associated with amyloid tau pathology, we sought to further characterize the bio-
chemical properties of aggregate-prone K280Q fibrils. Circular dichroism (CD) was employed to assess whether 
K280Q fibrils contained anti-parallel β -sheet structure, which strongly correlates with tau aggregation. As shown 
in Fig. 5, K280Q and P301L fibrils incubated for only 1 h showed the strongest shift in absorbance from random 
coil structure to β -sheet structure, as determined by the peak broadening observed at ~218 nm, a conformational 
transition previously noted for aggregate-prone tau fibrils and indicative of tau amyloid structure in vivo21,22. 
While WT fibrils displayed some detectable β -structure at the 1 h time-point, we note that the amyloid conversion 
Figure 3. Tau K280 acetylation-mimic enhances tau aggregation in vitro. (a) Coomassie blue staining of 
monomeric supernatant (S) and fibrillar pellet (P) fractions of tau-K18 fibril reactions (0 to 8 h). (b) Thioflavin 
T (ThT) fluorescence of tau-K18 fibril reactions at the indicated time points from 0 to 8 h. Error bars indicate s.d 
of the mean. (c) Coomassie blue staining of monomeric supernatant (S) and fibrillar pellet (P) fractions of full-
length tau-T40 fibril reactions (0 to 3 d). (d) ThT fluorescence of tau-T40 fibril reactions at the indicated time 
points from 0 to 3 d. Error bars indicate s.d of the mean derived from N = 3 independent experiments. Cropped 
images from full size gels are provided in panels a and c. Full-length gels are presented in Supplementary Fig. S4. 
Error bars indicate s.d. of the mean. Statistical significance was assessed using a student t-test (*p < 0.05; 
**p < 0.01; ***p < 0.001).
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for both WT and, more prominently, the K280R fibrils was reduced when compared to aggregate-prone K280Q 
or P301L mutants, also consistent with their delayed aggregation kinetics.
Fibrillar tau seeds promote the rapid appearance of K280-acetylated tau in mice13,23. We therefore tested 
whether expression of full-length tau containing acetylation-mimics, T40-2KQ (K280/281Q), was susceptible to 
seed-dependent tau aggregation in a cell-based assay. K18-P301L seeds were packaged and delivered into cultured 
QBI-293 cells ectopically expressing full-length tau-T40 (WT, P301L, 2KQ, or 2KR) and seeded tau pathology 
was assessed by immunoblotting of soluble and insoluble fractions. As expected, full-length T40-P301L partly 
accumulated in the insoluble fraction and was detectable with a panel of phospho-tau and acetyl-tau (ac-K280) 
antibodies (Fig. 6a and b, Supplementary Fig. S5). Similar to T40-P301L, full-length T40-2KQ also showed 
increased aggregation upon seeding and accumulated in the insoluble fraction, as detected with a total tau anti-
body (K9JA). In contrast, the T40-2KR non-mimic mutant was not significantly aggregated and behaved similarly 
to WT. Interestingly, unlike T40-P301L, which was hyper-phosphorylated at all epitopes examined, the insoluble 
T40-2KQ pool did not show robust phospho-tau immunoreactivity, indicating that tau hyper-phosphorylation 
does not necessarily correlate with insoluble tau seeding (Fig. 6b and Supplementary Fig. S5). Thus, 
acetylation-mimic tau mutations at residues K280/K281 are capable of enhancing the seed-dependent aggrega-
tion of full-length tau.
Cysteine oxidizing compounds modulate acetylation-induced tau aggregation. Given that 
the acetylation-mimics enhanced tau aggregation, we searched for compounds that might inhibit this process. 
Methylene blue (MB) and its derivatives are a class of anti-tau aggregation compounds, but their mechanism of 
action is not fully understood24–31. We tested whether MB inhibited WT and K280Q tau aggregation in vitro. Tau 
proteins were pre-incubated with MB prior to the initiation of fibril reactions. Consistent with previous reports, 
MB inhibited WT tau-K18 fibrillization as indicated by the delayed appearance of ~15 kDa tau-K18 in the fibril-
lar pellet fraction (Fig. 7a, left, Supplementary Fig. S6)26. Although K280Q showed accelerated fibril formation 
at 30 min, MB pre-treatment was also sufficient to partially delay K280Q aggregation at this time point, but was 
much less effective at 2 h, a time point at which K280Q had more fully transitioned to the fibrillar pellet fraction 
(Fig. 7a, right, Supplementary Fig. S6). The appearance of a ~30 kDa tau dimer was also observed in the presence 
of MB, consistent with its reported cysteine oxidizing properties26.
To assess the effects of MB on tau in cultured cells, we employed a previously described pharmacological 
strategy combining autophagy inhibition using 3-methyladenine (3MA) and exposure to the oxidative stressor 
Figure 4. Tau K280 acetylation-mimic fibrils show similar ultrastructural properties to P301L mutant tau. 
Negative staining electron microscopy (EM) of tau-K18 protein fibril reactions incubated for 2 h (top row) and 
4 h (bottom row). Scale bar, 500 nm.
www.nature.com/scientificreports/
7Scientific RepoRts | 7:44102 | DOI: 10.1038/srep44102
Figure 5. Tau K280 acetylation-mimic accelerates the formation of β-structure. (a–d) CD spectra of tau-
K18 fibril reactions at the indicated time points from 0 to 1 h (0 h, black line; 1 h, grey line) were recorded from 
190 to 250 nm. 0 h time points indicate monomeric soluble tau (random coil) and 1 h time point indicates 
fibrillar tau derived from the pellet fraction. Error bars indicate standard deviation (s.d.) of the mean derived 
from N = 3 independent experiments.
Figure 6. Tau acetylation-mimics enhance seed-dependent tau aggregation in cells. (a) Total and phospho-
tau immunoblotting of full-length tau-T40 expressing QBI-293 cells (WT, P301L, 2KQ, 2KR) seeded with 
K18-PL fibrils or, as a negative control, no fibril treatment (no fib). (b) Quantification of immunoblots in (a) was 
performed by protein band densitometry. Cropped images from full size immunoblots are provided in panel 
a. Full-length immunoblots and additional quantification are presented in Supplementary Fig. S5. Statistical 
significance was assessed using a student t-test (*p < 0.05; ***p < 0.001).
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sodium arsenite (Ars), which together stabilize the accumulation of aberrantly modified tau10. K18-WT, and more 
prominently K18-K280Q, accumulated in the soluble and also partially in the insoluble fractions in response to 
3MA and Ars, and their levels were suppressed by co-incubation with MB (Fig. 7b and c, Supplementary Fig. S6). 
Further implicating aberrant tau PTMs in this process, K18-P301L expressing cells showed increased K280 
acetylation and S262 phosphorylation within the MTBR, and these were also suppressed by co-incubation with 
MB (Supplementary Fig. S6). Thus, MB is sufficient to reduce aberrantly modified tau species in a cell-based 
assay, although we note that MB has broad pleiotropic effects in the cell that could also influence tau including 
regulation of tau kinases and caspases32,33.
Given the absence of ectopically expressed acetyltransferases in this cell-based assay, we hypothesized that 
MB may act, in part, by chemically interfering with endogenous tau acetylation, thereby decreasing aberrantly 
acetylated tau species and preventing their accumulation. Tau auto-acetylation was recently reported to occur in 
a cysteine-dependent manner in the complete absence of CBP/p300, in which acetyl-CoA reactive tau cysteines 
facilitate intrinsic tau acetylation on lysines7,10,34. Since MB is known to interact with tau cysteines24,26, we 
tested whether MB inhibits tau auto-acetylation using an in vitro radiolabeling assay (Supplementary Fig. S6). 
Inhibition of tau auto-acetylation was not observed with inactive control compounds. However, pre-incubation of 
K18-P301L with either MB or aminothienopyridazines (ATPZs), both of which are proposed to bind tau cysteines 
and promote their oxidation26, was sufficient to partially inhibit tau auto-acetylation (Supplementary Fig. S6). 
These results suggest that MB and related cysteine-interacting compounds could act, in part, via inhibition of tau 
auto-acetylation activity.
Discussion
In this study, we provide evidence that acetylation at residues K280/K281 is critical for normal and patholog-
ical tau functions. Site-specific tau acetylation was sufficient to alter the tau post-translational profile, impair 
tau-mediated MT stability, and accelerate tau aggregation. Furthermore, we provide evidence that acetylated 
full-length tau is more susceptible to seed-dependent tau aggregation, implicating tau acetylation in the patho-
genic cascade leading to tau pathology. These results warrant future efforts to target tau acetylation as a means to 
restore the stabilization of MTs, a process that is perturbed during the progression of AD and related tauopathies.
Figure 7. Methylene blue (MB) suppresses the accumulation of tau K280 acetylation-mimic. (a) Coomassie 
blue staining of monomeric supernatant (S) and fibrillar pellet (P) fractions of tau-K18 WT and K280Q 
fibril reactions in the absence of presence of MB. (b) Immunoblot analysis with indicated antibodies of cells 
expressing K18-WT or K18-K280Q treated with 3MA, Ars, and/or MB, where indicated. Hsc70 was included 
as a loading control. (c) Quantification of immunoblots in (b). Error bars indicate s.d. of the mean. Statistical 
significance was assessed using a student t-test (*p < 0.05; **p < 0.01; ***p < 0.001). Cropped images from full 
size gels and immunblots are provided in panels a and b. Full-length gels and immunoblots are presented in 
Supplementary Fig. S6.
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The identification of K280-acetylated tau in tauopathy brains initially presented a paradox regarding the sig-
nificance of this residue in neurodegeneration. How can both acetylation of K280, detected in AD and related 
4R-tauopathies, and the genetic deletion of the same residue, Δ K280 seen in FTDP-17 patients, both be mecha-
nistically linked to tauopathy? Given the critical role for residues K280/K281 in mediating MT interactions17,35–38, 
we propose that either acetylation-induced charge neutralization or complete deletion of lysines altogether yield 
comparable phenotypic consequences in reducing the positive charge and therefore the affinity of tau for MTs, 
thereby facilitating the accumulation of cytosolic tau aggregates. Indeed, either K → Q substitutions, expression of 
the acetyltransferase CBP/p300, or deletion of K280/K281 altogether (i.e. Δ K280/281) led to similar compensa-
tory tau dephosphorylation (Fig. 1) and loss of MT-stabilizing functions (Fig. 2). Thus, it is intriguing that a lysine 
PTM phenocopies a genetic lesion (e.g. Δ K280), providing a plausible explanation for how WT tau could become 
aggregated in the vast majority of sporadic tauopathies including AD. In fact, all 4R-tauopathies analyzed to date 
have shown some degree of tau K280 acetylation, which correlated most significantly with Thioflavin-positive 
mature NFTs in AD brains11,12. Importantly, however, unlike genetic tau mutations, abnormal tau PTMs such as 
acetylation provide a modifiable target for therapeutic intervention. Therefore, enhancement of deacetylase activ-
ity (e.g. HDAC6 or SIRT1)4,8,39 or inhibition of acetyltransferase activity (e.g. CBP/p300 or auto-acetyltransferase 
activity)4,8,10,15 could potentially alleviate tau aggregation and enhance normal tau functions. In this regard, the 
recent identification of salsalate as CBP/p300 inhibitor targeting tau K174 acetylation may also be effective at 
reducing K280 acetylation levels15. Future studies could evaluate whether any known or emerging CBP/p300 
inhibitors modulate K280/K281 acetylation.
In addition to CBP/p300, which is predominantly a nuclear enzyme involved in transcription and gene 
expression, our previous work suggested an intrinsic tau auto-acetylation activity capable of mediating tau 
self-acetylation via acetyl-CoA reactive cysteine residues10,34,40. Although the extent of tau auto-acetylation that 
occurs in vivo is not known, we speculate that a dedicated tau acetyltransferase may not be necessary to sustain 
increased tau acetylation in AD brain. Recent studies support the notion that physiological concentrations of 
acetyl-CoA cofactor alone could facilitate acetylation of cytoplasmic substrates41–43. Our results in vitro and in 
cell-based assays showed that MB or ATPZs, compounds that reportedly promote cysteine oxidation and pre-
vent tau aggregation, may also impair tau auto-acetylation. While we cannot rule out the contribution of other 
yet-to-be-identified tau acetyltransferases, our study suggests that cysteine oxidizing compounds might directly 
interfere with tau’s intrinsic cysteine-dependent acetyl group transfer, thereby modulating tau aggregation. 
Therefore, we speculate that any neuroprotective effects of MB and/or its derivatives could arise, in part, from 
their inhibition of tau acetylation in vivo. If so, future drug discovery efforts to identify compounds that selec-
tively target tau cysteines may represent viable approaches to prevent tau acetylation and limit the accumulation 
of tau pathology.
Given the complex post-translational regulation of tau by a variety of PTMs, we investigated potential 
cross-talk between acetylated tau and known pathological phospho-tau epitopes. Surprisingly, we found that tau 
acetylation led to its dephosphorylation at the AT8 epitope via PP2A phosphatase activity (Fig. 1). Elevated phos-
phatase activity likely acts in a compensatory manner to re-initiate tau-MT binding and/or prevent phospho-tau 
accumulation. The acetylation-induced dephosphorylation at AT8 is consistent with previous reports that AT8 
is a high affinity and preferred PP2A target site44–46. Interestingly, a transient reduction in AT8 immunoreactiv-
ity has been noted in a tau transgenic animal model47, indicating that fluctuations and/or dephosphorylation 
at the AT8 epitope could represent an intermediate step prior to subsequent pathological modifications. Since 
PP2A activity is impaired with AD progression48,49, AT8 might eventually re-emerge at later stages of disease pro-
gression characterized by tau hyper-phosphorylation and aggregation. Supporting this possibility, transient AT8 
reduction and recovery has been observed in cell culture models challenged with oxidative or cytoskeletal dam-
aging agents50,51. More recently, phosphorylation of one residue comprising the AT8 epitope (T205) was shown to 
be neuroprotective in response to excitotoxicity, suggesting that acetylation could promote toxicity by reducing 
T205 phosphorylation52. The complex relationship between tau acetylation and phosphorylation highlights an 
incomplete understanding of dynamic tau PTMs, and therefore global tau PTM analysis, as opposed to specific 
tau epitopes of interest, may provide more accurate predictors of tau pathogenesis.
Two prior observations hint at an involvement of tau acetylation in prion-like tau propagation. First, in both 
cell-based8 and tau transgenic mouse models4, increased Aβ levels were sufficient to induce tau acetylation, which 
could facilitate tau spreading into higher neocortical brain regions. Secondly, injection of recombinant tau fibrils 
into the hippocampus of PS19 mice led to intracellular tau acetylation within two weeks post-injection of fibrils13, 
an unexpected observation that may be linked to subsequent tau propagation in vivo. Here, full-length tau con-
taining K280/K281 acetylation-mimics (T40-2KQ) showed enhanced seed-dependent tau aggregation (Fig. 6). 
Since tau proteins are highly acetylated in AD brain, but not mutated in AD, it is conceivable that K280/K281 
acetylated tau may better reflect the pathogenic tau species capable of initial aggregation and subsequent prop-
agation in a spatiotemporal manner through the brain. More detailed biochemical analysis of the PTMs present 
on tau oligomers or other potentially transmissible tau species are necessary to further establish a causal link 
between acetylation and tau propagation.
In summary, our study highlights tau acetylation as a critical pathogenic mechanism that may confer both loss 
and gain of function toxicity in AD and related tauopathies. Given the central location of acetylated lysine clusters 
within the MTBR, we propose that acetylation, particularly at residues K280/K281 as well as other lysines that 
physically engage MTs, mediates loss of MT-regulatory function and gain of abnormal tau aggregation in spo-
radic tauopathies including AD. Since tau contains many lysines that are subject to acetylation, future approaches 
that merge genetic, biochemical, neuropathological, and physiological techniques will collectively be required to 
dissect this complex tau PTM code. These insights are essential to devise new therapeutic strategies designed to 
selectively modify specific tau PTMs in AD patients.
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Methods
Plasmids and Cell Culture. Two versions of human tau were used in this study. Most experiments used the 
full-length tau isoform containing both N-terminal inserts and all four repeat domains (2N4R-tau also designated 
tau-T40). The impact of MB and ATPZs used a fragment of tau comprising only the four repeat domains (desig-
nated tau-K18). All tau-T40 and tau-K18 plasmids were cloned into the pCDNA5/TO vector (Life Technologies). 
The Δ KK, K → Q, K → R, and P → L tau mutations were created using site-directed mutagenesis (NEB). In the 
tau-T40 and enzyme co-transfection experiments, the following enzyme plasmids were used: CBP WT, CBP LD, 
(CBP L1435A/D1436A), and HDAC6 (generous gifts from Tso-Pang Yao, Duke University, Durham, NC); GSK3 
(generous gift from Virginia M.-Y. Lee, University of Pennsylvania, Philadelphia, PA); and PP2A (PP2A-B56 α 
subunit, Addgene plasmid #14532). QBI-293 cells were grown in full DMEM media (supplemented with 10% 
FBS, 1X L-glutamine, and 1X penicillin/streptomycin), and FuGENE 6 transfection reagent (Promega) was used 
to perform the QBI-293 cell transfections.
Okadaic Acid (OA) Treatment Experiments. For OA treatment, QBI-293 cells transfected with tau-T40 
plasmids were treated with 25 nM OA for 16 h. Cells were lysed in RIPA buffer [50 mM Tris pH 8.0, 150 mM 
NaCl, 5 mM EDTA, 0.5% sodium deoxycholate, 1% Igepal CA-630, 0.1% SDS] supplemented with deacetylase, 
phosphatase and protease inhibitors as follows: 2 µ M Trichostatin A (TSA), 10 mM Nicotinamide (NCA), 1 mM 
sodium fluoride (NaF); 1 mM sodium orthovanadate (Na3VO4); 1 mM phenylmethylsulfonyl fluoride (PMSF); 
and protease inhibitor cocktail composed of L-1-tosylamide-2-phenylethylchloromethyl, N-tosyl-L-lysine chlo-
romethyl ketone, leupeptin, pepstatin, and soybean trypsin inhibitor, each at 1 µ g/ml). The samples were son-
icated 20 times and centrifuged at 15,000 rpm for 30 min at 4 °C and supernatants were resolved by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Neuronal Transfection and Fluorescent Microscopy. All animal studies were carried out in accordance 
with the University of North Carolina (UNC) Institutional Animal Care and Use Committee (IACUC). The ani-
mal protocol was approved by the UNC IACUC Committee (ID# Number: 14.107.0). Primary cortical neurons 
were cultured from E16 CD1 mouse embryos (Charles River) and were plated onto poly-D-lysine coated covers-
lips. Neuron transfection of 1 µ g of tau-GFP pCDNA was performed using CalPhos™ Mammalian Transfection 
Kit in accordance with manufacturer instructions (Clontech). Fixation was accomplished by incubating the cov-
erslips with 4% paraformaldehyde for 15 min, and cells were permeabilized by exposing coverslips to a 0.1% 
Triton X-100 in 1X PBS solution for 8 min to permeabilize the cells. Blocking was performed for 1 h at least an 
hour at room temperature in a solution of 2% milk in TBS containing 0.5% Triton. Following blocking, coverslips 
were then incubated in primary antibody, AT8 (1:1000), overnight at 4 °C. This was followed by staining with an 
Alexa Fluor® 594-conjugated secondary antibody and counterstaining with DAPI.
Mass spectrometry. NanoLC nanospray MS-MS analysis was performed at the University of Pennsylvania 
proteomics core facility, as previously described4. Briefly, QBI-293 cells were co-transfected with tau-T40 WT and 
CBP and tau was immunoprecipitated with T14/T46 antibodies. After separating tau via SDS-PAGE, gel bands 
were excised and submitted for mass spectrometry analysis using LTQ XL* Linear Ion Trap Mass Spectrometer 
(Thermo Scientific). Data was acquired using Xcalibur software (Thermo Scientific) and analyzed using Mascot, 
Scaffold, and PEAKS software programs. Unambiguously acetylated peptides were determined by significant 
10logP scores > 30 and mass accuracy scores < 1.0 ppm.
Protein Expression and Purification. Protein expression, extraction, and purification was performed 
using chromatography methodology to purify heat stable tau proteins. Tau-K18 and tau-T40 plasmids were 
cloned into the pRK172 bacterial expression vector for inducible protein expression. Protein was expressed in 
BL21 (DE3) RIL E. coli cells. Bacteria were grown in lysogeny broth, ampicillin was added, and when an OD of 1.0 
was reached, protein expression was induced with isopropyl-β -D-thiogalactopyranoside at a final concentration 
of 1.0 mM. After continued growth for 2 h, bacterial cultures were then centrifuged at 5,000 rpm for 15 min, and 
pellets were immediately frozen at − 80 °C. Pellets were resuspended in a high salt RAB buffer, pH 7.0 (0.1 M MES, 
1 mM EGTA, 0.5 mM MgSO4, 750 mM NaCl, 20 mM NaF, 0.1 mM PMSF, 0.1% protease inhibitor cocktail). This 
resuspension was homogenized, boiled, and centrifuged at 100,000 × g for 30 min. The resulting supernatant, with 
addition of 0.1 mM PMSF and 0.1% protease inhibitor cocktail, was dialyzed against FPLC buffer, pH 6.5 [20 mM 
piperazine-N,N’-bis(ethanesulfonic acid), 10 mM NaCl, 1 mM EGTA, 1 mM MgSO4, 0.1 mM PMSF and 2 mM 
dithiothreitol (DTT)]. After overnight dialysis, the contents were passed through a HiTrap sulfopropyl sepharose 
high performance cation exchange column (GE) attached to an ÄKTA Pure chromatography system equilibrated 
in FLPC buffer. Fractions were eluted over a 0–0.4 M NaCl gradient. Portions of the fractions were separated by 
SDS-PAGE and stained with Coomassie Blue R-250. Fractions containing tau protein were subsequently pooled. 
The FPLC buffer present in pooled tau protein fractions was exchanged for 100 mM sodium acetate (pH 7.0), and 
protein was concentrated using Amicon Ultra centrifugal filter devices (Millipore Corporation, Billerica, MA). 
Resultant protein concentration was determined using bicinchoninic acid assay (Thermo Scientific Pierce).
Tau Fibrillization Reactions. For sedimentation analysis, Thioflavin T, and negative stain electron micros-
copy, a concentration of 10 µ M tau-K18 was incubated without agitation at 37 °C with 10 µ M heparin (Sigma) and 
2 mM DTT in a 100 mM sodium acetate buffer (pH 7.0). In the MB sedimentation experiments, a fibril reaction 
mixture with 10 µ M tau-K18 and 50 µ M MB (Sigma) was held on ice for 15 minutes prior to adding heparin 
to a final concentration of 10 µ M. Tau-T40 incubations were performed in a similar fashion, but used 15 µ M 
tau-T40/15 µ M heparin and were agitated at 37 °C. Fibril reactions for circular dichroism and cell seeding assay 
used 20 µ M tau-K18/20 µ M heparin.
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Sedimentation Analysis by SDS-PAGE. Tau fibril reactions were centrifuged at 15,000 rpm for 30 min 
at 4 °C to separate supernatant and pellet fractions. The pellet fraction was resuspended in 1X loading buffer and 
100 mM DTT and an equal mass of supernatant was mixed with 6X loading buffer and 100 mM DTT. Equal mass 
supernatant and pellet fractions for various reaction times were separated by SDS-PAGE followed by Coomassie 
blue staining to detect tau protein.
Thioflavin T (ThT) Fluorescence Assay. The ThT signal of tau-K18 and tau-T40 fibril reactions at various reac-
tion times was measured at 430 nm (excitation) and 500 nm (emission) in a 10 µ M ThT solution using a FLUOstar 
Omega microplate reader (BMG LABTECH, Germany). Into each well, 15 µl of protein and 150 µl of 10 µM ThT solu-
tion was added. The plate was shaken briefly in the plate reader, and then the measurements were performed.
Negative Staining Electron Microscopy (EM). For EM experiments, 5 µL of 10 µ M tau-K18 fibril 
reactions were placed on 400 mesh Formvar/Carbon film-coated copper grids (Ted Pella, Inc.) for 5 min, 
quickly washed with distilled water two times, and then stained with 2% uranyl acetate for 30 sec. A LEO 
EM910 transmission electron microscope (Carl Zeiss Microscopy) at an acceleration voltage of 80 kV was used 
to visualize the fibrils. The camera used was an Orius SC1000 CCD Camera, 2672 × 4008 pixels (11 megapix-
els) and Digital Micrograph version 2.3 software was used to acquire the images (Gatan, Inc.). A minimum 
of N = 10 independent regions of each grid was imaged from N = 3 independent replicates of WT, K280Q, or 
P301L mutant fibrils.
Circular Dichroism (CD). Measurements for CD were performed with a ChirascanTM circular dichroism 
spectrometer (Applied Photophysics Ltd, United Kingdom) using a cuvette with a 0.10 cm path length. CD 
data was collected from 190 nm to 250 nm at 0.5 nm intervals. For the 0 h time point, 20 µM of the tau-K18 
monomer in 100 mM sodium acetate buffer was dialyzed overnight against the CD buffer [10 mM potassium 
phosphate, 100 mM potassium fluoride pH 7.0]. For 1 h time point, CD spectra were generated using 20 µ M 
tau fibril reaction pellet fractions resuspended in CD buffer.
Tubulin Polymerization Assay. Tubulin polymerization at 37 °C was monitored via absorbance readings at 
350 nm using a FLUOstar Omega microplate reader (BMG LABTECH, Germany). Polymerization reactions con-
tained 2 mM GTP (Sigma), 55 µ M purified tubulin (Cytoskeleton), and 40 µM purified tau-K18 protein (or no tau 
in case of control). The reactions were carried out in PEM buffer [80 mM piperazine-N,N’-bis(ethanesulfonic acid) 
pH 6.9, 0.5 mM EGTA, 2 mM MgCl2 hexahydrate]. Absorbance data was collected at 1 min intervals for 45 min.
Methylene Blue (MB) Cell Treatment Assay. QBI-293 cells transfected with tau-K18 WT, K280Q, or 
P301L were treated with 10 µ M MB before and after treatment with 10 mM 3-methyladenine (3MA) and 40 µ 
M sodium arsenite (Ars). After overnight treatment with MB, 3MA and Ars, the cells were lysed on ice and 
sequential extraction was performed. Cells were lysed in RIPA buffer [50 mM Tris pH 8.0, 150 mM NaCl, 5 mM 
EDTA, 0.5% sodium deoxycholate, 1% Igepal CA-630, 0.1% SDS] supplemented with deacetylase, phosphatase 
and protease inhibitors (2 µ M TSA, 10 mM NCA, 1 mM NaF; 1 mM Na3VO4; 1 mM PMSF; and protease inhib-
itor cocktail). The samples were sonicated 20 times and centrifuged at 15,000 rpm for 30 min at 4 °C. Another 
extraction was performed on the pellet fraction using urea buffer [7 M urea, 2 M thiourea, 4% CHAPS, 30 mM 
Tris pH 8.5] supplemented with the same deacetylase, phosphatase, and protease inhibitors as the RIPA buffer. 
The samples were sonicated 10 times and centrifuged at 15,000 rpm for 30 min at room temperature. For radi-
olabeling experiments, total tau proteins (1 µ g total protein) were acetylated by incubation in 30 µ l of reaction 
buffer (50 mM Tris-HCl pH 8.0, 10% glycerol, 1 mM DTT, 100 mM EDTA, 1 mM PMSF, and 10 nCi [14C]-labeled 
acetyl-CoA acetyl-CoA) for 1 h at 37 °C. Acetylation reactions were pre-incubated for 10 min with 20 µ M MB or 
active/inactive ATPZ compounds, which were kindly provided by Dr. Kurt Brunden (University of Pennsylvania).
Tau-K18 Fibril Seeding Assay. QBI-293 cells transfected with indicated tau-T40 plasmids were trans-
duced with tau-K18-PL fibrils or no fibril control. Each fibril treated well of the 6-well plate received 6 µ g of 
tau-K18-PL fibrils. Fibrils treatments were prepared by resuspending pellets from tau-K18-PL fibril reactions 
in OptiMEM and then sonicating this mixture 30 times. No fibril controls were OptiMEM alone. The sonicated 
fibrils (or no fibril controls) were then added to OptiMEM plus Lipofectamine2000 (Invitrogen) and allowed 
to stand for 20 min at room temperature. This fibril-Lipofectamine mixture was added to the transfected 
cells. After an overnight incubation, cell culture media was replaced with fresh, full DMEM media. Cells were 
lysed 44–48 h after fibril addition. They were harvested on ice into Triton X-100 lysis buffer [1% Triton X-100, 
150 mM NaCl, 50 mM Tris pH 7.6] supplemented with deacetylase, phosphatase and protease inhibitors [3 µ M 
TSA, 10 mM NCA, 1 mM NaF; 1 mM Na3VO4; 1 mM PMSF; and protease inhibitor cocktail]. The samples 
were sonicated 30 times and centrifuged at 15,000 rpm for 30 min at 4 °C. The supernatant was reserved as the 
Triton-soluble fraction. A second Triton X-100 extraction was performed on the pellet using the same parameters 
as the first Triton X-100 extraction. The last extraction of the pellet was performed using SDS lysis buffer [1% 
SDS, 150 mM NaCl, 50 mM Tris pH 7.6] supplemented with the same deacetylase, phosphatase, and protease 
inhibitors as the Triton X-100 lysis buffer. The samples were sonicated 30 times and centrifuged at 15,000 rpm for 
30 min at room temperature. The resulting supernatant was reserved as the Triton-insoluble SDS fraction.
Immunoblotting and antibodies. Cell lysates were resolved via SDS-PAGE (on 10% gels for tau-T40 and 
15% gels for tau-K18), transferred to nitrocellulose membrane (Biorad), and blocked with 2% milk in 1X TBS for 
30 min. Membranes were incubated with primary antibody overnight at 4 °C, followed by a 1 h room temperature 
incubation with HRP-conjugated anti-mouse or anti-rabbit antibodies (1:1000). The following primary antibod-
ies were used: pSer202/pThr205-tau (AT8, 1:1000, Thermo Fisher Scientific, MN1020), pSer262-tau (p-S262, 
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1:1000, Thermo Fisher Scientific, 44-750G), pThr231-tau (AT180, 1:1000, Thermo Fisher Scientific, MN1040), 
pThr181-tau (AT270, 1:1000, Thermo Fisher Scientific, MN1050), tau-1 (1:1000, Millipore, MAB3420), 
pSer396-tau (p-S396, Thermo Fisher Scientific, 44-752G), anti-acetylated K280-tau4 (ac-K280, 1:1000), tau K9JA 
(total tau, 1:5000, Dako, A0024), tau-T46 (1:1000, Thermo Fisher Scientific, 13-6400), and Hsc70 (1:1000, Enzo 
Life Sciences, SPA-815). ImageJ software (NIH) was used to quantify band intensity.
Statistical analysis. Comparison between two groups were analyzed using a student t-test. Significance is 
presented with *, **, and ***corresponding to p < 0.05, p < 0.01, and p < 0.001, respectively. Error bars represent 
the SD of the mean. Statistical analysis was performed using GraphPad Prism software.
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